Emmaus Life Sciences (OTC: EMMA) is a specialty pharmaceutical company that commercializes Endari (pharmaceutical-grade L-glutamine oral powder) for the treatment of sickle cell disease. Revenue is generated through product sales of Endari, which received FDA approval and is sold in the United States and through exclusive distribution agreements with regional partners in international markets. The company is a single-product commercial-stage business; it suspended further research and development activities in late 2024, incurring only $0.3 million in R&D expenses in FY2025 versus $0.7 million in FY2024. International expansion is pursued via exclusive distribution partners in the Gulf Cooperation Council countries and the broader MENA region, with marketing authorizations approved in the UAE (March 2022), Qatar (November 2022), Kuwait (December 2022), Bahrain (May 2023), and Oman (July 2023), and an application pending in Saudi Arabia. An early access agreement also covers France, the Netherlands, and the U.K. The company operates under the holding entity EMI Holding, Inc. and is headquartered in the Pacific Center office space.

Revenue model

Transactional product sales of Endari (L-glutamine oral powder) to patients and healthcare facilities in the U.S., supplemented by distribution revenue through exclusive regional partners in the MENA region and early access arrangements in select European markets.

Products and services

Endari (pharmaceutical-grade L-glutamine oral powder): FDA-approved treatment for sickle cell disease in patients age five and older. Clinical trial results through Week 48 showed reduction in sickle cell crises, fewer hospitalizations for sickle cell pain, fewer cumulative days hospitalized, longer time to first crisis, and lower incidence of acute chest syndrome versus placebo.

Customers and end markets

Patients with sickle cell disease (age five and older) treated through hospitals, emergency care facilities, and outpatient settings in the U.S. International end markets include GCC countries and the broader MENA region, plus early access markets in France, the Netherlands, and the U.K.

Value-chain role

Commercial-stage pharmaceutical company that licenses and sells an FDA-approved branded prescription product. Relies on third-party manufacturers subject to cGMP requirements. Intellectual property protection rests on trademark rights, trade secret protection, distribution agreements, and manufacturing agreements rather than patents. International commercialization is conducted through exclusive regional distribution partners.

Geographic exposure

United States (primary commercial market); Gulf Cooperation Council and broader MENA region via exclusive distribution agreements (marketing authorizations in UAE, Qatar, Kuwait, Bahrain, and Oman as of FY2025; application pending in Saudi Arabia); early access distribution in France, the Netherlands, and the U.K.

Source: SEC 10-K, filed 2026-03-31

Industry: Pharmaceutical Preparations Peers: CLS Holdings USA, Inc. Adial Pharmaceuticals Inc Artelo Biosciences Inc CNS Pharmaceuticals Inc GB SCIENCES INC Johnson & Johnson Range Impact Inc Palisade Bio Inc